- Home
- PRA vs OPT Comparison
PRA vs OPT Comparison
Compare PRA & OPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRA
- OPT
- Stock Information
- Founded
- PRA 1976
- OPT 1984
- Country
- PRA United States
- OPT Australia
- Employees
- PRA N/A
- OPT N/A
- Industry
- PRA Property-Casualty Insurers
- OPT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PRA Finance
- OPT Health Care
- Exchange
- PRA Nasdaq
- OPT Nasdaq
- Market Cap
- PRA 851.8M
- OPT 767.9M
- IPO Year
- PRA N/A
- OPT 2020
- Fundamental
- Price
- PRA $15.67
- OPT $3.91
- Analyst Decision
- PRA Buy
- OPT Strong Buy
- Analyst Count
- PRA 3
- OPT 1
- Target Price
- PRA $17.67
- OPT $12.00
- AVG Volume (30 Days)
- PRA 255.6K
- OPT 9.3K
- Earning Date
- PRA 02-25-2025
- OPT 08-30-2024
- Dividend Yield
- PRA N/A
- OPT N/A
- EPS Growth
- PRA N/A
- OPT N/A
- EPS
- PRA 0.84
- OPT N/A
- Revenue
- PRA $1,162,157,000.00
- OPT $261,859.00
- Revenue This Year
- PRA N/A
- OPT N/A
- Revenue Next Year
- PRA $0.56
- OPT $46,864.64
- P/E Ratio
- PRA $18.66
- OPT N/A
- Revenue Growth
- PRA 2.62
- OPT N/A
- 52 Week Low
- PRA $10.76
- OPT $1.79
- 52 Week High
- PRA $17.79
- OPT $5.45
- Technical
- Relative Strength Index (RSI)
- PRA 38.83
- OPT 61.76
- Support Level
- PRA $15.50
- OPT $3.15
- Resistance Level
- PRA $16.11
- OPT $3.39
- Average True Range (ATR)
- PRA 0.45
- OPT 0.17
- MACD
- PRA -0.13
- OPT 0.07
- Stochastic Oscillator
- PRA 10.00
- OPT 100.00
About PRA ProAssurance Corporation
ProAssurance Corp is a holding company for property and casualty insurance companies. The company's wholly-owned insurance subsidiaries provide professional liability insurance for healthcare professionals and facilities, professional liability insurance for attorneys, and workers' compensation insurance. ProAssurance reports operating results in five segments: Specialty Property and Casualty, Workers' Compensation, Segregated Portfolio Cell Reinsurance, Lloyd's Syndicate, and Corporate. ProAssurance generates the vast majority of its revenue from its Specialty P&C activities, followed by Worker's Compensation.
About OPT Opthea Limited
Opthea Ltd operates in one industry being the medical technology and healthcare. It is focused on developing biological therapeutics for eye diseases. The company is developing a novel biologic therapy, OPT-302, for the treatment of eye diseases. Its products are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors C and D and R3 targets. Opthea's development activities are based on an intellectual property portfolio covering key targets Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. The company geographically operates Australia and United States.